{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O76096",
      "entity_text" : "CMAP",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:O75923",
      "entity_text" : "Dysferlin",
      "features" : [ {
        "modification_type" : "unknown",
        "feature_type" : "modification"
      } ],
      "entity_type" : "gene_or_gene_product"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "We hypothesized that if the CMAP defect caused by loss of Dysferlin was similar to that found in myasthenic conditions, then the Dysferlin CMAP defect might be improved via AchE.I therapy.",
  "reading_complete" : "2020-08-04T10:22:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:21:30Z",
  "trigger" : "caused",
  "evidence" : [ "CMAP defect caused by loss of Dysferlin" ],
  "pmc_id" : "3828772",
  "score" : 0
}